NASDAQ: SVRA

Savara Inc.

Healthcare | Biotechnology

No licensed closing price on file for SVRA. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

Savara Inc. (NASDAQ: SVRA) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-21 08:28 UTC.

What Savara Inc. does

Savara Inc. is a clinical stage biopharmaceutical company developing MOLBREEVI, an inhaled biologic containing recombinant human GM-CSF for autoimmune pulmonary alveolar proteinosis, a rare lung disease. The company's sole product candidate is in Phase 3 development, with a pivotal trial that enrolled patients and reported positive results, followed by a biologics license application submission to the FDA. MOLBREEVI is delivered through a proprietary eFlow Nebulizer System supplied by PARI under a long-term agreement.

Summarized from Savara Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation	8-K 2026-06-08
Return on equity	-77.06%
Debt/equity	0.21

Charts

Charts are in the appInteractive charts for SVRA are available in Oxford Ledge.
Open SVRA in Oxford Ledge →

SEC Filings

SEC EDGAR ↗

Recent Insider Activity (last 90 days)

Source: SEC EDGAR · Filed 2026-09-25

2026-09-25Chief Commercial OfficerTax withholding-29,323$148.7K
2026-07-24Chief Fin. & Operating OfficerStock Option (Right to Buy)Award70,000—
2026-07-24Chief Fin. & Operating OfficerAward35,000—

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q2

NEA Management Company, LLC24,471,264$150.74M0.0%
Bain Capital Life Sciences Investors, LLC17,600,621$108.42M0.0%
Venrock Adviser, LLC14,745,943$90.84M+7.3%

View QoQ ownership changes →Full institutional ownership →

Recent 8-K Events (parsed from SEC filings)All events →

Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

2025-01-23Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2024-04-12Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersRicky SunEstimatedSEC 8-K →
2024-01-25Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →

Company news

View all →

Savara Has Lost 30% Since December: JPMorgan Sees 146% Upside
Yahoo2026-10-11
What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timeline
fool.com2026-06-27
Savara CFO to step down
Seeking Alpha Markets2026-06-08
Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference
businesswire.com2026-04-14

Questions this page answers

What does Savara Inc. do?

Savara Inc. is a biotechnology company, listed on NASDAQ as SVRA.

When did SVRA last file with the SEC?

Savara Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-08. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-21 08:28 UTC. This page is also available as JSON at /api/data?ticker=SVRA and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for SVRA and 5,000+ tickers.

Create a free account — keep SVRA

For your agent

GET /api/data?ticker=SVRA

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt